anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sepsis is a widespread and life-threatening disease characterised by infection-triggered immune hyperactivation and cytokine storms, culminating in tissue damage and multiple organ dysfunction syndrome. BMAL1 is a pivotal transcription factor in the circadian clock that plays a crucial role in maintaining immune homeostasis. BMAL1 dysregulation has been implicated in inflammatory diseases and immunodeficiency. However, the mechanisms underlying BMAL1 disruption in sepsis-induced acute lung injury (ALI) remain poorly understood. In vitro, we used THP1 and mouse peritoneal macrophages to elucidate the potential mechanism of BMAL1 function in sepsis. In vivo, an endotoxemia model was used to investigate the effect of BMAL1 on sepsis and the therapeutic role of targeting CXCR2. We showed that BMAL1 significantly affected the regulation of innate immunity in sepsis-induced ALI. BMAL1 deficiency in the macrophages exacerbated systemic inflammation and sepsis-induced ALI. Mechanistically, BMAL1 acted as a transcriptional suppressor and regulated the expression of CXCL2. BMAL1 deficiency in macrophages upregulated CXCL2 expression, increasing the recruitment of polymorphonuclear neutrophils and the formation of neutrophil extracellular traps (NETs) by binding to the chemokine receptor CXCR2, thereby intensifying lung injury in a sepsis model. Furthermore, a selective inhibitor of CXCR2, SB225002, exerted promising therapeutic effects by markedly reducing neutrophil infiltration and NETs formation and alleviating lung injury. Importantly, CXCR2 blockade mitigated multiple organ dysfunction. Collectively, these findings suggest that BMAL1 controls the CXCL2/CXCR2 pathway, and the therapeutic efficacy of targeting CXCR2 in sepsis has been validated, presenting BMAL1 as a potential therapeutic target for lethal infections.
FIELD: medicine. ^ SUBSTANCE: present invention refers to medical products, particularly to water-soluble concentrated lipoid emulsions prepared by a high-pressure homogeniser from lecithins and/or phospholipids, lipids and strong solutions of polyatomic alcohols or carbohydrates. Herewith solutions of polyatomic alcohols as related to carbohydrate are concentrated as 30 to 99 wt % respectively with ratio of lecithin and/or phospholipid to lipid is 1:1 to 1:12, while mixed lecithin and/or phospholipid and lipid in solution of polyatomic alcohol as related to carbohydrate is concentrated 10 to 90 wt %. Besides the invention concerns application of said concentrated emulsions. ^ EFFECT: preparation of transparent dissolved emulsions. ^ 11 cl, 2 ex
The present invention relates to skin care formulations including octapeptide complexes. A preferred embodiment of the skin care formulation is a multi-active serum, which treats numerous skin problems associated with environmental exposure and aging. In one aspect, the multi-serum may be formulated for treatment of facial skin, and may optionally be applied as a mask. In another aspect, the multi-active serum may be formulated specifically for the treatment of delicate skin in the under-eye area of the fact. This embodiment of the invention may be applied as an under-eye mask. In yet another aspect, the invention provides a method of manufacturing skin formulations including octapeptide complexes.
In this study, 60 volunteers without any prior exposure to traditional or digital impressions took part. Using a C-type impression medium, conventional impressions of the maxillary and mandibular dental arches were taken. Digital impressions are taken using an intra-oral scanner at the same appointment. Following the impressions, a standardized questionnaire was used to assess the individuals' attitudes, preferences, and perceptions of the impression procedures. The Wong-Baker Pain Rating Scale was used to assess the perceived source of stress and Frankl Behavioural Scale was used for assessing behaviour. After taking the impression, the processing phases of the impression techniques (working time, etc.), and parental satisfaction were noted.
OBJECTIVES: Epilepsy care in China has expanded considerably in the last decade but still remains largely unknown; we developed an easy-to-use tool to assess its quality.
METHODS: We adapted the Epilepsy Update Quality Measurement, produced by the American Academy of Neurology (AAN) for use in China: The Quality Indicator for Epilepsy Treatment-China National Action (QUIET-CHINA). This tool incorporates a standardized case report form initially for logging quality indicators for people with epilepsy during in-patient stays. Nine quality indicators covered seizures, drugs, diagnostics, screening for co-morbid conditions, counseling for woman of child bearing age, and a composite indicator was further proposed by total number of interventions performed divided by the total number of people eligible in each indicator. The tool also has an electronic reporting and data feedback system. 96 epilepsy centers in 31 jurisdictions in mainland China have been piloted since 2017.
RESULTS: Data from 11,600 individuals with epilepsy in the first 3-year study period were analyzed. The median age was 31; 60% were male. The composite indicators were 74%. Seizure freedom rate was less than 25% in all epilepsy types and post-surgical seizure freedom rate was 21%. 90% had seizure type and frequency, antiepileptic drugs recorded, while only 70% with active epilepsy were on regular antiepileptic drugs treatment. Investigations for diagnosis and etiology were performed in around 90% but screening for co-morbid conditions and counseling for women of childbearing potential was 38% and 15% respectively. Severe side effect happened in 2% individuals during the treatment.
CONCLUSION: The preliminary results of the national action provided some baseline information. Except for an overall improvement, a significant treatment gap still exists, and psychiatric co-morbidities or issues affecting women are not seen as a priority. QUIET-CHINA will be expanded to more and other levels of hospitals, to help narrow the treatment gap and equalize the comprehensive epilepsy care on the national level.
Silicosis is a complex occupational disease without recognized effective treatment. Celastrol, a natural product, has shown antioxidant, anti-inflammatory, and anti-fibrotic activities, but the narrow therapeutic window and high toxicity severely limit its clinical application. Through structural optimization, we have identified a highly efficient and low-toxicity celastrol derivative, CEL-07. In this study, we systematically investigated the therapeutic potential and underlying mechanisms of CEL-07 in silicosis fibrosis. By constructing a silicosis mouse model and analyzing with HE, Masson, Sirius Red, and immunohistochemical staining, CEL-07 significantly prevented the progress of inflammation and fibrosis, and it effectively improved the lung respiratory function of silicosis mice. Additionally, CEL-07 markedly suppressed the expression of inflammatory factors (IL-6, IL-1α, TNF-α, and TNF-β) and fibrotic factors (α-SMA, collagen I, and collagen III), and promoted apoptosis of fibroblasts by increasing ROS accumulation. Moreover, bioinformatics analysis combined with experimental validation revealed that CEL-07 inhibited the pathways associated with inflammation (PI3K-AKT and JAK2-STAT3) and the expression of apoptosis-related proteins. Overall, these results suggest that CEL-07 may serve as a potential candidate for the treatment of silicosis.
PURPOSE:To obtain a preventive for dental caries having proliferation-inhibiting effect against Streptococcus mutans by extracting KANJU (rhizome of Dryopteris crassirhizoma) with methanol, fractionating the extract with a dialysis tube and using the obtained fraction having a specific molecular weight as an active component. CONSTITUTION:KANJU is extracted with methanol and the components soluble in a non-hydrophilic organic solvent are removed from the extract to obtain an aqueous solution. The solution is put into a dialysis tube having a fractional molecular weight of 1,000 and dialyzed with water. The inner liquid is put into a dialysis tube having a fractional molecular weight of 10,000 and dialyzed with water to fractionate into an inner liquid and an outer liquid and obtain NPF-87KAN-I having a molecular weight of 1,000-10,000 and NPF-87KAN-II having a molecular weight of >=10,000. Both fractions are separately subjected to high-performance liquid chromatography and each fraction is separated into two fractions (IA having a molecular weight of 8,100, IB having a molecular weight of 4,900, IIA having a molecular weight of 12,800 and IIB having a molecular weight of 9,400). KAN-I is a mixture of IA and IB at a ratio of about 1:6 and KAN-II is a mixture of IIA and IIB at a ratio of about 1:4. Both fractions have comparable activities for the inhibition of the growth of Streptococcus mutans.
OBJECTIVE: Patients with epilepsy have high risk of experiencing uncommon causes of death. This study aimed to evaluate patients who underwent unusual deaths related to epilepsy and identify factors that may contribute to these deaths and may also include sudden unexpected death in epilepsy (SUDEP).
METHODS: We analyzed 5291 cases in which a postmortem imaging (PMI) study was performed using plane CT, because of an unexplained death. A rapid troponin T assay was performed using peripheral blood samples. Clinical information including the cause of death suspected by the attending physician, body position, place of death, medical history, and antiseizure medications was evaluated.
RESULTS: A total of 132 (2.6%) patients had an obvious history of epilepsy, while 5159 individuals had no history of epilepsy (97.4%). Cerebrovascular disease was the cause of death in 1.6% of patients in the group with epilepsy, and this was significantly lower than that in the non-epilepsy group. However, drowning was significantly higher (9.1% vs. 4.4%). Unspecified cause of death was significantly more frequent in the epilepsy group (78.0% vs. 57.8%). Furthermore, the proportion of patients who demonstrated elevation of troponin T levels without prior cardiac disease was significantly higher in the epilepsy group (37.9% vs. 31.1%). At discovery of death, prone position was dominant (30.3%), with deaths occurring most commonly in the bedroom (49.2%). No antiseizure medication had been prescribed in 12% of cases, while 29.5% of patients were taking multiple antiseizure medications.
SIGNIFICANCE: The prevalence of epilepsy in individuals experiencing unusual death was higher than in the general population. Despite PMI studies, no definitive cause of death was identified in a significant proportion of cases. The high troponin T levels may be explained by long intervals between death and examination or by higher incidence of myocardial damage at the time of death.
PLAIN LANGUAGE SUMMARY: This study investigated unusual deaths in epilepsy patients, analyzing 5291 postmortem imaging cases. The results showed that 132 cases (2.6%) had a clear history of epilepsy. In these cases, only 22% cases were explained after postmortem examination, which is less than in non-epilepsy group (42.2%). Cerebrovascular disease was less common in the epilepsy group, while drowning was more common. Elevated troponin T levels, which suggest possibility of myocardial damage or long intervals between death and examination, were also more frequent in the epilepsy group compared to non-epilepsy group.
Methods and systems for actively and adaptively cancelling the noise and vibration generated by medical devices. A method includes receiving data from one or more sensors (404, 406) of a medical device (400). The method includes determining a signature signal using a processing unit (202/302) for the medical device based at least on the data. The signature signal is a representation of one or more physical byproducts of the medical device, and one or more environmental conditions of a physical environment proximate to the medical device. The method incudes determining an inverted signal using an inverted signal generation module (232) based on the signature signal, the inverted signal configured to mask the signature signal. The method includes generating a physical representation of the inverted signal by one or more electrical or electromechanical components(422, 424) of the medical device, and masking the signature signal with the inverted signal.
Trauma is the leading cause of death for adults under the age of 44. Internal bleeding remains a significant challenge in medical emergencies, necessitating the development of effective hemostatic materials that could be administered by paramedics before a patient is in the hospital and treated by surgeons. In this study, we introduce a graphene oxide (GO)-based PEGylated synthetic hemostatic nanomaterial with an average size of 211 ± 83 nm designed to target internal bleeding by mimicking the role of fibrinogen. Functionalization of GO-g-PEG with peptides derived from the α-chain of fibrinogen, such as GRGDS, or the γ-chain of fibrinogen, such as HHLGGAKQAGDV:H12, was achieved with peptide loadings of 72 ± 6 and 68 ± 15 μM, respectively. In vitro studies with platelet-rich plasma (PRP) under confinement demonstrated aggregation enhancement of 39 and 24% for GO-g-PEG-GRGDS and GO-g-PEG-H12, respectively, compared to buffer, while adenosine diphosphate (ADP) alone induced a 5% aggregation. Compared to the same materials in the absence of ADP, GO-g-PEG-GRGDS achieved a 47% aggregation enhancement, while GO-g-PEG-H12 a 25% enhancement. This is particularly important for injectable hemostats and highlights the fact that our nanographene-based materials can only act as hemostats in the presence of agonists, reducing the possibility of unwanted clotting during circulation. Further studies on collagen-coated wells under dynamic flow revealed statistically significant augmentation of PRP fluorescence signal using GRGDS- or H12-coated GO-g-PEG compared to controls. Hemolysis studies showed <1% lysis of red blood cells (RBCs) at the highest PEGylated nanographene concentration. Finally, whole human blood coagulation studies reveal faster and more pronounced clotting using our nanohemostats vs PBS control from 3 min and below (blood is clotted with 10% CaCl2 within 4-5 min), with the biggest differences to be shown at 2 and 1 min. At 1 min, the clot weight was found to be ∼45% of that between 4 and 5 min, while no clot was formed in PBS-treated blood. Reduction of CaCl2 to 5 and 3%, or utilization of prostaglandin E1, an anticoagulant, still leads to clots but of smaller weight. The findings highlight the potential of our fibrinogen-mimic PEGylated nanographene as a promising non-hemolytic injectable scaffold for targeting internal bleeding, offering insights into its platelet aggregation capabilities under confinement and under dynamic flow as well as its pronounced coagulation abilities.
Computer-aided detection (CADe) based on artificial intelligence (AI) may improve quality of colonoscopy. An increasing number of young endoscopists are trained in an AI environment, however its impact on trainees future outcomes remains unclear. The study aimed to evaluate quality indicators of endoscopists trained in an AI environment compared to those trained conventionally. A study included 6,000 adult patients who underwent a colonoscopy for various reasons. The study retrospectively evaluated the first 1,000 procedures performed by six endoscopists after completing training relying entirely on endoscopists detection skills without AI enhancement. Three of those young endoscopists were trained with CADe, and three without additional assistance. Quality indicators were assessed in both groups. The morphology of detected polyps was evaluated to determine the influence of AI-enhanced training on laterally spreading tumors (LST) detection rate.
Participants in the intervention group received a 28-day AI conversation intervention after completing the baseline questionnaire. We asked users in the intervention group to use the web link every day, upload the start and end times of their conversations with the AI bot and screenshots of their chats; users who chatted for more than 5 minutes were considered to have successfully punched in for that day. Participants who clocked more than 8 days in the first 14 days were allowed to complete the second questionnaire at the two-week mark. Similarly, participants who quit more than eight times between days 15 and 28 could complete the third questionnaire at the four-week mark. Therefore, all users in the intervention group who completed the third questionnaire received at least 16 AI conversation interventions.
BACKGROUND: Variable number tandem repeats (VNTRs) are highly polymorphic DNA regions harboring many potentially disease-causing variants. However, VNTRs often appear unresolved ("dark") in variation databases due to their repetitive nature. One particularly complex and medically relevant VNTR is the KIV-2 VNTR located in the cardiovascular disease gene LPA which encompasses up to 70% of the coding sequence.
RESULTS: Using the highly complex LPA gene as a model, we develop a computational approach to resolve intra-repeat variation in VNTRs from largely available short-read sequencing data. We apply the approach to six protein-coding VNTRs in 2504 samples from the 1000 Genomes Project and developed an optimized method for the LPA KIV-2 VNTR that discriminates the confounding KIV-2 subtypes upfront. This results in an F1-score improvement of up to 2.1-fold compared to previously published strategies. Finally, we analyze the LPA VNTR in > 199,000 UK Biobank samples, detecting > 700 KIV-2 mutations. This approach successfully reveals new strong Lp(a)-lowering effects for KIV-2 variants, with protective effect against coronary artery disease, and also validated previous findings based on tagging SNPs.
CONCLUSIONS: Our approach paves the way for reliable variant detection in VNTRs at scale and we show that it is transferable to other dark regions, which will help unlock medical information hidden in VNTRs.
Both groups will receive an intravenous chemotherapeutic drug (carboplatin). The second study group (n=6) will receive dexamethasone for 3 weeks, then switch to bevacizumab, the antiangiogenic agent, for 3 weeks.
The present invention relates to a Chinese medicine composition which can be used for nourishing Yin, reinforcing the spleen, removing stagnation and lowering the adverse rise of energy, a preparation method and application thereof. The Chinese medicine composition belongs to the field of Chinese medicine preparation. The Chinese medicine composition is made into the mixture from the following medicinal materials according to the percent by weight: 14 to 16% of dwarf lilyturf tuber, 14 to 16% of polygonatum, 14 to 16% of common yan rhizome, 14 to 16% of cochinchinese asparagus root, 23 to 25% of parched hawthorn fruit and 18 to 20% of areca seeds. The medicinal materials are decocted by water and condensed into paste whose relative density is from 1.1 to 1.2 at the temperature of 60 DEG C, a corrector and an addition agent are added, and the water is added until the compounding total amount is reached. Thereby, the mixture is obtained. The composition can also be made into particles, or powder, or tablets, or capsules, or oral liquid, or sugar syrup. The present invention gives priority to the dwarf lilyturf tuber and the polygonatum to nourish the stomach and promote the production of body fluid. The common yan rhizome is utilized to nourish Yin and reinforce the spleen. In addition, the cochinchinese asparagus root is added so as to strengthen the salivation promoting force of the stomach, reinforce the middle-Zhou, promote the salivation and supply the body fluid, namely, the six hollow viscera are replenished under the condition of keeping the dredging function. The parched hawthorn fruit and the areca seeds are taken as adjuvants so as to remove the stagnation, clear the hollow viscera and send down the flatulence to perform the replenishing and dredging efficiency. The Chinese medicine composition invigorates yin and clear the hollow viscera. Therefore, the Chinese medicine composition has good curative effect on people with anorexia, xerostomia.
Current understanding of what sustains public health programs is derived primarily from evaluations of programs delivered for only a few years. To improve program planning and knowledge on program sustainment, we examined real-world population programs that have been delivered for >2 years. Our focus was physical activity and nutrition programs for obesity prevention. We identified programs through published literature and searched through publicly available information on the theoretical factors determining sustainment. We reviewed 90 programs and explored intervention characteristics, provider, delivery and process level factors, and the outer environment influences. Programs were sustained on average 15 years and more frequently characterised as behavioural change skills programs targeting children, funded by non-government organisations and delivered by community organisations. Most programs had undergone some modification (n = 55). Differences between programs were observed across key factors: Programs sustained 15+ years were mainly behaviour skills programs (n = 21); and characterised by interactive designs (i.e., face-to-face or digital) over static innovations (i.e., print material) compared with those sustained <15 years (p = 0.024). While government funding supported many of the programs (n = 45;), those sustained 15+ years were more likely to have been commercially funded (p = 0.044); and were less likely to have current community involvement (p = 0.013). Differences in ownership and funding were also observed across countries. While multiple factors may influence program sustainment, longer delivered programs where distinguished by their program characteristics and outer contextual factors, suggesting such factors may have an important role in sustaining programs in the longer-term.
PURPOSE:To prepare uniform liposome good in a chemical agent holding rate, by a method wherein the componential substance of a liposome membrane is mixed with a volatile org. solvent and, after the org. solvent is removed under stirring, the obtained uniform mixture is dispersed in an aqueous solution. CONSTITUTION:About 0.1-8pts.wt. of a volatile org. solvent is added to and mixed with 1pts.wt. of the componential substance of a liposome membrane (phosphatidyl choline) and the org. solvent is removed under stirring or kneading to form a uniform mixture. In this case, a membrane stabilizer (cholesterol), a charging substance (diacetyl phosphate) and an oxidation inhibitor (alpha-tocopherol) may be added to the membrane componential substance if necessary. Subsequently, an aqueous solvent (water or a physiological saline solution) is added to the uniform mixture in a ratio of 10-1,000pts.wt. to 1pts.wt. of the membrane componential substance to swell liposome at the phase transition temp. of lipid and the resulting mixture is further finely dispersed to prepare liposome.
Patients with severe Chronic Periodontitis having a pocket depth (PD) of ≥5 mm and a clinical attachment level (CAL) ≥5 mm. Open flap debridement (surgical periodontal therapy) will be carried out for these patients after scaling \& root planing.
Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11; and mitoxantrone IV, etoposide IV over 1 hour, and intermediate-dose cytarabine IV over 6 hours on days 1-6. Treatment continues in the absence of disease progression or unacceptable toxicity.
Participants were to complete 13 cycles of drospirenone (DRSP) and ethinylestradiol (EE) use. Each cycle was 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received a total of 21 tablets of DRSP-EE per cycle. Each tablet contained 3 mg DRSP and 30 μg EE.